ConductScience.org, home

Paper28314976

Enzyme replacement therapy and beyond-in memoriam Roscoe O. Brady, M.D. (1923-2016).

Ries M. J Inherit Metab Dis, 2017. Cited by 38 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Enzyme replacement therapy and beyond-in memoriam Roscoe O. Brady, M.D. (1923-2016). Papers, record 28314976. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28314976

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Enzyme replacement therapy and beyond-in memoriam Roscoe O. Brady, M.D. (1923-2016).
PubMed
Journal
J Inherit Metab Dis
PubMed
Year
2017
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
38
iCite
Relative citation ratio, by iCite
1.62
iCite
Revised in PubMed
2021-01-09
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ries MMarkushttps://orcid.org/0000-0002-5054-5741

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Lysosomal Storage DiseasesMajor topic
Animals
Biomarkers
Clinical Trials as Topic
Enzyme Replacement Therapy
Genetic Therapy
Humans
Lysosomes
Molecular Chaperones

Source PubMed

Download CSV of topics

References90

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
121417264Strategies for Neoglycan conjugation to human acid α-glucosidase.Bioconjug Chem2011https://conductscience.org/library/papers/21417264PubMed
24236721Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts.Science1968https://conductscience.org/library/papers/4236721PubMed
322167193Ex vivo and in vivo effects of isofagomine on acid β-glucosidase variants and substrate levels in Gaucher disease.J Biol Chem2012https://conductscience.org/library/papers/22167193PubMed
422279584CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder.PLoS One2012https://conductscience.org/library/papers/22279584PubMed
519750228Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression.PLoS One2009https://conductscience.org/library/papers/19750228PubMed
615669681Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease.J Inherit Metab Dis2004https://conductscience.org/library/papers/15669681PubMed
718713755Reversal of peripheral and central neural storage and ataxia after recombinant enzyme replacement therapy in alpha-mannosidosis mice.Hum Mol Genet2008https://conductscience.org/library/papers/18713755PubMed
812803917Biosynthesis and degradation of mammalian glycosphingolipids.Philos Trans R Soc Lond B Biol Sci2003https://conductscience.org/library/papers/12803917PubMed
910801168Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.Lancet2000https://conductscience.org/library/papers/10801168PubMed
1019775699Twice-daily cysteamine bitartrate therapy for children with cystinosis.J Pediatr2010https://conductscience.org/library/papers/19775699PubMed
1125688781Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial.JAMA2015https://conductscience.org/library/papers/25688781PubMed
1223194248Gene therapy for mucopolysaccharidosis type VI is effective in cats without pre-existing immunity to AAV8.Hum Gene Ther2013https://conductscience.org/library/papers/23194248PubMed
1321496291Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders.Orphanet J Rare Dis2011https://conductscience.org/library/papers/21496291PubMed
147985893Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources.Ann Intern Med1995https://conductscience.org/library/papers/7985893PubMed
1515126990Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).J Pediatr2004https://conductscience.org/library/papers/15126990PubMed
164236091The defect in Hurler's and Hunter's syndromes: faulty degradation of mucopolysaccharide.Proc Natl Acad Sci U S A1968https://conductscience.org/library/papers/4236091PubMed
179883849Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor.Nat Med1999https://conductscience.org/library/papers/9883849PubMed
1819067373Randomized, controlled trial of miglustat in Gaucher's disease type 3.Ann Neurol2008https://conductscience.org/library/papers/19067373PubMed
1911703994Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy.Am J Cardiol2001https://conductscience.org/library/papers/11703994PubMed
2011439963Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.N Engl J Med2001https://conductscience.org/library/papers/11439963PubMed

See all 90 referencesDownload CSV of references

Cited by23

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 38 citations.

PMIDTitleJournalYearIn PapersSource
40710901Advances in Diagnosis, Pathological Mechanisms, Clinical Impact, and Future Therapeutic Perspectives in Tay-Sachs Disease.Neurol Int2025https://conductscience.org/library/papers/40710901PubMed
39105852The role of ceranib-2 and its nanoform on the decrease of telomerase levels in human non-small cell cancer.Mol Biol Rep2024https://conductscience.org/library/papers/39105852PubMed
38738088Current Concepts in the Management of Sanfilippo Syndrome (MPS III): A Narrative Review.Cureus2024https://conductscience.org/library/papers/38738088PubMed
38664313Advances in Immune Tolerance Induction in Enzyme Replacement Therapy.Paediatr Drugs2024https://conductscience.org/library/papers/38664313PubMed
37654562Precocious puberty in patients with Pompe disease.Front Endocrinol (Lausanne)2023https://conductscience.org/library/papers/37654562PubMed
36566487Modifying enzyme replacement therapy - A perspective.J Cell Mol Med2023https://conductscience.org/library/papers/36566487PubMed
36534309Recent topics and advanced therapies in chronic granulomatous disease.Hum Cell2023https://conductscience.org/library/papers/36534309PubMed
36412587
A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease.
Int J Neonatal Screen2022https://conductscience.org/library/papers/36412587PubMed
35865957Therapeutic Strategies For Tay-Sachs Disease.Front Pharmacol2022https://conductscience.org/library/papers/35865957PubMed
35036673Lysosome-Targeting Strategy Using Polypeptides and Chimeric Molecules.ACS Omega2022https://conductscience.org/library/papers/35036673PubMed
34835710Tween® Preserves Enzyme Activity and Stability in PLGA Nanoparticles.Nanomaterials (Basel)2021https://conductscience.org/library/papers/34835710PubMed
34199011Nanofibrous Formulation of Cyclodextrin Stabilized Lipases for Efficient Pancreatin Replacement Therapies.Pharmaceutics2021https://conductscience.org/library/papers/34199011PubMed
33766102New paradigms for the treatment of lysosomal storage diseases: targeting the endocannabinoid system as a therapeutic strategy.Orphanet J Rare Dis2021https://conductscience.org/library/papers/33766102PubMed
33711910Current and emerging pharmacotherapy for Gaucher disease in pediatric populations.Expert Opin Pharmacother2021https://conductscience.org/library/papers/33711910PubMed
33417459Relevance of Electrostatics for the Interaction of Tyrosine Hydroxylase with Porous Silicon Nanoparticles.Mol Pharm2021https://conductscience.org/library/papers/33417459PubMed
32267884FDA orphan drug designations for lysosomal storage disorders - a cross-sectional analysis.PLoS One2020https://conductscience.org/library/papers/32267884PubMed
31209777Therapeutic Options for Mucopolysaccharidoses: Current and Emerging Treatments.Drugs2019https://conductscience.org/library/papers/31209777PubMed
30442189Enzyme replacement therapy: efficacy and limitations.Ital J Pediatr2018https://conductscience.org/library/papers/30442189PubMed
30318473Coexpression of novel furin-resistant LPL variants with lipase maturation factor 1 enhances LPL secretion and activity.J Lipid Res2018https://conductscience.org/library/papers/30318473PubMed
30004274Digital microfluidics comes of age: high-throughput screening to bedside diagnostic testing for genetic disorders in newborns.Expert Rev Mol Diagn2018https://conductscience.org/library/papers/30004274PubMed

See all 23 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28314976

GET https://conductscience.org/api/papers/v1/28314976/references?page=2